Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharmaceuticals Inc.

Other

Aventis Pharmaceuticals Products Inc.

Eli Lilly and Company

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Aventis Pharmaceuticals Product, Inc.

Michael R Myers

Alfred P Spada

Martin P Maguire

Paul E Persons

Wei He

Cynthia Anne Fink

William R Ewing

Yong Mi Choi-Sledeski

Henry W Pauls

Asher Zilberstein

Susan E Johnson

Chin-Yi Jenny Hsu

Siegfried Stengelin

Gerhard Jaehne

Christopher J Burns

Timothy Francis Gallagher

Heinz W Pauls

Andreas W Herling

Chuan Shih

Stephen M Condon

Jolie Anne Bastian

Kent W Neuenschwander

Sajan Joseph

Guenter Mueller

Joseph M Karpinski

Antony Bigot

Mark Andrew Pobanz

Robert D Groneberg

Robert L Morris

Aiwen Li

Gregory Bernard Poli

Barbara Hanney

Mary Margaret Mader

Benoit J Vanasse

Jean-Francois Sabuco

Michael R Becker

Renhua Li

Tiechao Li

Kevin John Hudziak

Boyu Zhong

John Ziqi Jiang

Christopher Randall Schmid

Mark A Bobko

Aktham Aburub

Roderick S Davis

Laurence W Reilly

Alfonso De Dios

Beatriz López De Uralde-Garmendia

Wan F Lau

Franz Jakob Hock

Jenny Pingqi Dai

Cuong Q Ly

Martin P Maquire

Jesus Andres Blas De Blas

An underwater personal vehicle that as twin battery powered motors affixed to a central body. The propellers preferably counter-rotate and are in shrouds to allow true tracking without stabilizing fins. The operator holds onto the device and controls it from handles on the aft end of the central body. A light and supplemental ballast tubes are available. The thrust produced by the motors is at approximately the center of mass of the vehicle to further stabilize it during motion.

Personal underwater vehicle

4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt thereof as Akt inhibitors that are antineoplastic and/or antiviral agents as well as compositions comprising these compounds and methods of using these compounds.

Inhibitors of AKT (protein kinase B)

The present invention provides kinase inhibitors of Formula (I). Wherein R, R, X and Z are as described herein, or a pharmaceutically acceptable salt thereof. 

Kinase inhibitors

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are independently 0, 1, 2, or 3, provided that n+p is a least 1; These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.

Adenosine analogues and their use as pharmaceutical agents

A tool installs barb emitters in irrigation tubing. The tool has a cradle which receives irrigation tubing and a punch mounted opposite the cradle. The punch has a first cylinder and a second cylinder telescopically received within the first cylinder. The first cylinder has a cap at the upper end and an annular ring extending inwardly from to partially occlude the lower end. The second cylinder includes a second cap at the upper end which slidably engages the first cylinder and is resiliently urged by a spring against the annular ring. The cap has a punch holder extending downwardly therefrom. A needle has a sharp tip extending downwardly from the punch holder through the second cap to a point within the second cylinder when the spring is fully extended and beyond the second cylinder when the spring is fully compressed. One of the jaws has a knife blade extending from the other end thereof opposite. The of the jaws defines a semi-circular concave anvil at the other end. The anvil has an axially extending slot therein which receives the cutting edge of said knife blade when the handles are closed together.

Installation tool for irrigation emitter barbs with cutter

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase

A tool installs barb emitters in irrigation tubing. The tool has a cradle which receives irrigation tubing and a punch mounted opposite the cradle. The punch has a first cylinder and a second cylinder telescopically received within the first cylinder. The first cylinder has a cap at the upper end and an annular ring extending inwardly from to partially occlude the lower end. The second cylinder includes a second cap at the upper end which slidably engages the first cylinder and is resiliently urged by a spring against the annular ring. The cap has a punch holder extending downwardly therefrom. A needle has a sharp tip extending downwardly from the punch holder through the second cap to a point within the second cylinder when the spring is fully extended and beyond the second cylinder when the spring is fully compressed.

Installation tool for irrigation emitter barbs

Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties

Growing community of inventors

Reading, PA, United States of America

Michael R Myers